01-12-2008 | Research Articles
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
Published in: Clinical and Translational Oncology | Issue 12/2008
Login to get access